Cargando…
Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer
Previous studies show that dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhances the antitumor efficacy of dexamethasone (DEX) in drug-resistant breast cancer involving cancer stem-like cells (CSCs). In this study, we investigated the pharmacokinetic (PK) properties of SUL in nude m...
Autores principales: | Yao, Qing-yu, Li, Jian, Chen, Rong, Yao, Ye, Xue, Jun-sheng, Chen, Wen-jun, Lu, Wei, Zhou, Tian-yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470835/ https://www.ncbi.nlm.nih.gov/pubmed/31165782 http://dx.doi.org/10.1038/s41401-019-0251-7 |
Ejemplares similares
-
Binding of Sulpiride to Seric Albumins
por: da Silva Fragoso, Viviane Muniz, et al.
Publicado: (2016) -
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015) -
Sulpiride Serves, a Substrate for the Gut Microbiome
por: Mukhtar, Imran, et al.
Publicado: (2021) -
In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015) -
Overcoming the Drawbacks of Sulpiride by Means of New Crystal Forms
por: Birolo, Rebecca, et al.
Publicado: (2022)